Discounted Cash Flow (DCF) Analysis Levered
Enzo Biochem, Inc. (ENZ)
$1.2697
+0.02 (+1.58%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Actual | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
| Revenue | 81.17 | 76.02 | 117.73 | 107.07 | 31.06 | 28.61 | 26.36 | 24.28 | 22.37 | 20.61 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | 4.81 | -17.18 | 0.39 | -16.59 | -36.98 | -8.63 | -7.95 | -7.33 | -6.75 | -6.22 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -8.13 | -2.17 | -4.44 | -3.47 | -2.76 | -1.65 | -1.52 | -1.40 | -1.29 | -1.19 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -3.32 | -19.35 | -4.05 | -20.06 | -39.74 | -10.28 | -9.47 | -8.72 | -8.04 | -7.40 |
Weighted Average Cost Of Capital
| Share price | $ 1.2,697 |
|---|---|
| Beta | 0.907 |
| Diluted Shares Outstanding | 49.16 |
| Cost of Debt | |
| Tax Rate | 181.08 |
| After-tax Cost of Debt | -4.05% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.603 |
| Total Debt | 7 |
| Total Equity | 62.42 |
| Total Capital | 69.42 |
| Debt Weighting | 10.08 |
| Equity Weighting | 89.92 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Actual | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected | 2028 Projected |
| Revenue | 81.17 | 76.02 | 117.73 | 107.07 | 31.06 | 28.61 | 26.36 | 24.28 | 22.37 | 20.61 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.81 | -17.18 | 0.39 | -16.59 | -36.98 | -8.63 | -7.95 | -7.33 | -6.75 | -6.22 |
| Capital Expenditure | -8.13 | -2.17 | -4.44 | -3.47 | -2.76 | -1.65 | -1.52 | -1.40 | -1.29 | -1.19 |
| Free Cash Flow | -3.32 | -19.35 | -4.05 | -20.06 | -39.74 | -10.28 | -9.47 | -8.72 | -8.04 | -7.40 |
| WACC | ||||||||||
| PV LFCF | -9.58 | -8.22 | -7.06 | -6.06 | -5.20 | |||||
| SUM PV LFCF | -36.11 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 7.33 |
| Free cash flow (t + 1) | -7.55 |
| Terminal Value | -141.68 |
| Present Value of Terminal Value | -99.47 |
Intrinsic Value
| Enterprise Value | -135.58 |
|---|---|
| Net Debt | -75.38 |
| Equity Value | -60.20 |
| Shares Outstanding | 49.16 |
| Equity Value Per Share | -1.22 |